Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Price Up 8.3% – Should You Buy?

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) shot up 8.3% during trading on Thursday. The stock traded as high as $0.5279 and last traded at $0.52. 6,570 shares were traded during trading, a decline of 98% from the average session volume of 340,033 shares. The stock had previously closed at $0.48.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, July 5th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $53.33.

Reviva Pharmaceuticals Stock Performance

The firm has a market cap of $6.82 million, a price-to-earnings ratio of -0.28 and a beta of 0.50. The company has a 50 day moving average price of $0.49 and a 200 day moving average price of $0.76.

Reviva Pharmaceuticals (NASDAQ:RVPH) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.19. On average, research analysts forecast that Reviva Pharmaceuticals Holdings, Inc. will post -2.96 earnings per share for the current year.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders. The company’s research is based on its proprietary drug-discovery platform, which is designed to identify medicines that act on multiple serotonin and dopamine receptors.

Reviva’s lead product candidate is brilaroxazine, formerly known as RP5063. Brilaroxazine is an investigational multimodal serotonin-dopamine activity modulator being developed for schizophrenia and other neuropsychiatric and inflammatory conditions, including bipolar depression, major depressive disorder, and certain dementia-related psychoses.